Exact Imaging Revenue and Competitors

Markham, ON CAN

Location

$25.4M

Total Funding

Estimated Revenue & Valuation

  • Exact Imaging's estimated annual revenue is currently $4.9M per year.(i)
  • Exact Imaging's estimated revenue per employee is $125,500
  • Exact Imaging's total funding is $25.4M.

Employee Data

  • Exact Imaging has 39 Employees.(i)
  • Exact Imaging grew their employee count by 26% last year.

Exact Imaging's People

NameTitleEmail/Phone
1
VP, Engineering and ClinicalReveal Email/Phone
2
Director FinanceReveal Email/Phone
3
Director AdministrationReveal Email/Phone
4
Director, Verification & ValidationReveal Email/Phone
5
Director, Regulatory Affairs & Quality AssuranceReveal Email/Phone
6
Manager Global Clinical Application SpecialistsReveal Email/Phone
7
Crucial Projects Leader / Interim Global Product ManagerReveal Email/Phone
8
Snr Quality Engineering SpecialistReveal Email/Phone
9
Clinical Application Specialist, North AmericaReveal Email/Phone
10
President and CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$31.1M124-4%N/AN/A
#2
$4M16-6%N/AN/A
#3
$78.3M3129%N/AN/A
#4
$23.1M926%N/AN/A
#5
$9.3M379%N/AN/A
#6
$75.3M2403%$53.9MN/A
#7
$267.6M106613%N/AN/A
#8
$36.6M0N/A$1.3BN/A
#9
$30.9M123-20%N/AN/A
#10
$8.5M34-17%N/AN/A
Add Company

What Is Exact Imaging?

Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVuâ„¢ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For the minority of cases where MRI might assist (i.e., prior negative biopsies), FusionVuâ„¢ is the micro-US/MRI fusion application operating on the ExactVu micro-ultrasound platform - - and guided by the system's 70 micron real-time resolution. The ExactVu micro-ultrasound system, including FusionVu, has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).

keywords:N/A

$25.4M

Total Funding

39

Number of Employees

$4.9M

Revenue (est)

26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Exact Imaging News

2022-04-17 - Micro-Ultrasound Systems Market Size And Forecast | Phillips ...

... Micro Medical Devices, FUJFILM VisualSonics Inc., Hitachi Medical Systems, Exact Imaging, GE Healthcare, Carestream Health.

2022-04-17 - Global Micro-ultrasound Systems Market Leading ...

Exact Imaging; FUJFILM; Carestream; Hitachi Medical. The report also highlights the product type: Non-invasive Imaging; In-vivo Imaging.

2022-04-13 - Improved Survival With Enzalutamide in Patients With ...

... Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, Ferring,...

2017-01-05 - Exact Imaging Secures CDN $21.5M in Series C Funding

Exact Imaging, a Toronto, Canada-based developer of high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, secured CDN $21.5m in Series C funding. The round, which closed late in 2016, was co-led by Lumira Capital (Toronto, ON) and Vesalius Bio ...

2017-01-05 - Exact Imaging secures CDN $21.5 Million in financing to support the commercialization of its new disruptive ExactVu™ micro-ultrasound for prostate imaging and biopsy

TORONTO, Jan. 5, 2017 /PRNewswire/ – Exact Imaging (www.exactimaging.com), the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has secured CDN $21.5 million in a Series C investment to commercialize its Exac ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.9M4146%N/A
#2
$4.4M42-18%N/A
#3
$8.2M428%N/A
#4
$5M43-25%N/A
#5
N/A4416%N/A